US congressional report slams FDA approval of Alzheimer's drug

The US Food and Drug Administration’s approval process for a controversial drug used to treat Alzheimer’s was “rife with irregularities,” a congressional report said Thursday.

An 18-month investigation into the FDA’s green-lighting of the drug, Aduhelm, also criticized its manufacturer, biotechnology company Biogen.

Legit : Read More